Literature DB >> 8223799

Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.

G Saggese1, S Bertelloni, G I Baroncelli, R Battini, G Franchi.   

Abstract

Gonadal steroids drive the significant bone mineral increase that occurs at puberty. Oestrogen deprivation in women results in bone loss. We investigated bone mineralization by single photon absorptiometry in girls with central precocious puberty (n = 13, age 3.8-8.5 years) before and during 1 year of treatment with gonadotropin releasing hormone analogue (GnRH-a = long-acting D-Trp6-GnRH, 60 micrograms i.m. every 28 days). Before GnRH-a therapy, bone mineral density (BMD) was significantly higher in patients than in ten control girls matched for chronological age (patients 0.575 +/- 0.097 g/cm2, controls 0.433 +/- 0.049 g/cm2, P < 0.001). Patient BMD was not significantly different from that of ten control girls matched according to patient bone, age (0.550 +/- 0.046 g/cm2, P = NS). During GnRH-a treatment, pituitary-gonadal axis was suppressed and patient BMD significantly decreased (6 months: -6.0%, P < 0.002 vs baseline; 12 months: -8.0%, P < 0.001 vs baseline). We conclude that in girls with precocious puberty the activation of gonadal steroid secretion induces an increase in bone mineralization and that oestrogen deprivation by GnRH-a treatment caused a significant decrease in BMD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223799     DOI: 10.1007/bf01953983

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.

Authors:  W H Matta; R W Shaw; R Hesp; R Evans
Journal:  Clin Endocrinol (Oxf)       Date:  1988-07       Impact factor: 3.478

2.  Relationship between local and total bone mineral in normal pubertal boys.

Authors:  S Krabbe; A Gotfredsen; C Christiansen
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

3.  Bone mineral status in growth hormone deficiency.

Authors:  R M Shore; R W Chesney; R B Mazess; P G Rose; G J Bargman
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

4.  Diagnosis and management of precocious puberty.

Authors:  M D Wheeler; D M Styne
Journal:  Pediatr Clin North Am       Date:  1990-12       Impact factor: 3.278

5.  Growth velocity and serum aminoterminal propeptide of type III procollagen in precocious puberty during gonadotropin-releasing hormone analogue treatment.

Authors:  G Saggese; S Bertelloni; G I Baroncelli; G Di Nero; R Battini
Journal:  Acta Paediatr       Date:  1993-03       Impact factor: 2.299

6.  Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters.

Authors:  C Glastre; P Braillon; L David; P Cochat; P J Meunier; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

Review 7.  Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.

Authors:  P A Boepple; M J Mansfield; M E Wierman; C R Rudlin; H H Bode; J F Crigler; J D Crawford; W F Crowley
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

8.  Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue.

Authors:  R Stanhope; P J Pringle; C G Brook
Journal:  Acta Paediatr Scand       Date:  1988-07

9.  Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; L Cinquanta; G Di Nero
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

10.  Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.

Authors:  S Waibel-Treber; H W Minne; S H Scharla; T Bremen; R Ziegler; G Leyendecker
Journal:  Hum Reprod       Date:  1989-05       Impact factor: 6.918

View more
  9 in total

1.  Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.

Authors:  Simone Kapteijns-van Kordelaar; Kees Noordam; Barto Otten; Joop van den Bergh
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

2.  Fractures in spina bifida from childhood to young adulthood.

Authors:  A Trinh; P Wong; J Brown; S Hennel; P R Ebeling; P J Fuller; F Milat
Journal:  Osteoporos Int       Date:  2016-08-24       Impact factor: 4.507

Review 3.  Transgender medicine - puberty suppression.

Authors:  Leonidas Panagiotakopoulos
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

4.  How Do Drugs Affect the Skeleton? Implications for Forensic Anthropology.

Authors:  Nicholas Márquez-Grant; Elisa Baldini; Victoria Jeynes; Lucie Biehler-Gomez; Layla Aoukhiyad; Nicholas V Passalacqua; Gaia Giordano; Domenico Di Candia; Cristina Cattaneo
Journal:  Biology (Basel)       Date:  2022-03-29

Review 5.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.

Authors:  S Bertelloni; G I Baroncelli; M C Sorrentino; G Perri; G Saggese
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

7.  An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D.

Authors:  A Kaya; A Cayir; M I Turan; B Ozkan
Journal:  West Indian Med J       Date:  2015-01-21       Impact factor: 0.171

8.  Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.

Authors:  Sandra B Alessandri; Francisco de A Pereira; Rosângela A Villela; Sonir R R Antonini; Paula C L Elias; Carlos E Martinelli; Margaret de Castro; Ayrton C Moreira; Francisco J A de Paula
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 9.  Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty.

Authors:  Eun Young Kim
Journal:  Korean J Pediatr       Date:  2015-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.